20th Canadian Melanoma Conference 2026 - Friday, February 27, 2026

Programs and Speakers

By proceeding, you agree that OncologyEducation may anonymize any provided information, and use it for marketing research and/or promotional purposes.

Question Title

1. Occupation (please check one):

Physician (Internal Medicine)

Medical Oncologist

Radiation Oncologist

Surgeon

Surgical Oncologist

Nurse

Pharmacist

Resident / Fellow

Industry / Pharmaceutical Company

Dermatologist

Other (please specify)

Question Title

2. Please provide the authors names and titles of any CLINICAL TRIALS presented today, CMC 2026 Day 2, that you found impactful and would like more detailed information.

Question Title

3. Please rate the sessions as follows in regards to their relevance to you or how it will change your practice.

	Excellent	Very Good	Good	Fair	Poor
Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard	Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard Excellent	Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard Very Good	Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard Good	Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard Fair	Merck Breakfast Symposium: Two Decades of Progress: Transforming the Melanoma Journey – Past, Present, and Future - Prof. Caroline Robert, Dr. Teresa Petrella and Kathy Barnard Poor
Address from Save Your Skin - Kathy Barnard	Address from Save Your Skin - Kathy Barnard Excellent	Address from Save Your Skin - Kathy Barnard Very Good	Address from Save Your Skin - Kathy Barnard Good	Address from Save Your Skin - Kathy Barnard Fair	Address from Save Your Skin - Kathy Barnard Poor
Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin	Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin Excellent	Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin Very Good	Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin Good	Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin Fair	Neoadjuvant Systemic Therapy in Melanoma: Present and Future - Dr. Sapna Patel and Prof. James Larkin Poor
The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff	The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff Excellent	The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff Very Good	The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff Good	The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff Fair	The Pathologist’s Role in Neoadjuvant Therapy in Melanoma - Dr. Michael Tetzlaff Poor
The Surgical Oncologist Perspective - Prof. Alexander van Akkooi	The Surgical Oncologist Perspective - Prof. Alexander van Akkooi Excellent	The Surgical Oncologist Perspective - Prof. Alexander van Akkooi Very Good	The Surgical Oncologist Perspective - Prof. Alexander van Akkooi Good	The Surgical Oncologist Perspective - Prof. Alexander van Akkooi Fair	The Surgical Oncologist Perspective - Prof. Alexander van Akkooi Poor
Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi	Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi Excellent	Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi Very Good	Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi Good	Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi Fair	Neoadjuvant Therapy in Melanoma Panel Discussion and Q&A - Dr. James Larkin, Dr. Michael Tetzlaff and Prof. Alexander van Akkooi Poor
Flash Talks (Resident Oral Poster Session)	Flash Talks (Resident Oral Poster Session) Excellent	Flash Talks (Resident Oral Poster Session) Very Good	Flash Talks (Resident Oral Poster Session) Good	Flash Talks (Resident Oral Poster Session) Fair	Flash Talks (Resident Oral Poster Session) Poor
Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton	Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton Excellent	Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton Very Good	Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton Good	Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton Fair	Initial Diagnosis, Management, and Risk Stratification of Uveal Melanoma - Dr. Katherine Paton Poor
Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff	Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff Excellent	Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff Very Good	Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff Good	Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff Fair	Systemic Therapy for Advanced Uveal Melanoma - Dr. Marlana Orloff Poor
Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes	Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes Excellent	Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes Very Good	Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes Good	Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes Fair	Radiation for Locally Advanced Skin Cancers (SCC, Merkel Cell & BCC) - Dr. Toni Barnes Poor
Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes	Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes Excellent	Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes Very Good	Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes Good	Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes Fair	Rare Melanoma Subtypes (Uveal) Panel Discussion, Cases and Q&A - Dr. Katherine Paton, Dr. Marlana Orloff and Dr. Toni Barnes Poor
BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella	BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella Excellent	BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella Very Good	BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella Good	BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella Fair	BMS Lunch Symposium: How Do I Choose? Case-Based Discussion on 1L treatment Selection - Dr. Ahmad Tarhini, Dr. Sapna Patel and Dr. Teresa Petrella Poor
Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain	Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain Excellent	Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain Very Good	Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain Good	Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain Fair	Treating Patients with Autoimmune Disease: What To Do When Checkpoint Blockade is Relatively Contraindicated - Dr. Pauline Funchain Poor
GI Toxicity - Dr. Michael Dougan	GI Toxicity - Dr. Michael Dougan Excellent	GI Toxicity - Dr. Michael Dougan Very Good	GI Toxicity - Dr. Michael Dougan Good	GI Toxicity - Dr. Michael Dougan Fair	GI Toxicity - Dr. Michael Dougan Poor
Lung Toxicity - Dr. Shane Shapera	Lung Toxicity - Dr. Shane Shapera Excellent	Lung Toxicity - Dr. Shane Shapera Very Good	Lung Toxicity - Dr. Shane Shapera Good	Lung Toxicity - Dr. Shane Shapera Fair	Lung Toxicity - Dr. Shane Shapera Poor
Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera	Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera Excellent	Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera Very Good	Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera Good	Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera Fair	Immunotherapy Toxicity Cases & Discussion - Dr. Shaqil Kassam, Dr. Pauline Funchain, Dr. Michael Dougan and Dr. Shane Shapera Poor
Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow	Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow Excellent	Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow Very Good	Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow Good	Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow Fair	Overcoming Resistance to Immunotherapy in Advanced Melanoma - Dr. Michael Postow Poor
Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner	Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner Excellent	Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner Very Good	Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner Good	Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner Fair	Incorporating TIL Therapy in 2025 in Advanced Melanoma and What the Future Might Hold - Dr. Allison Betof Warner Poor
Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert	Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert Excellent	Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert Very Good	Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert Good	Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert Fair	Novel Strategies and Targets in Treating Advanced Melanoma - Prof. Caroline Robert Poor
Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner	Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner Excellent	Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner Very Good	Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner Good	Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner Fair	Advanced Melanoma Panel Discussion and Q&A - Prof. Caroline Robert, Dr. Michael Postow and Dr. Allison Betof Warner Poor
Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy	Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy Excellent	Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy Very Good	Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy Good	Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy Fair	Clinicopathology Cases - Dr. Joël Claveau, Dr. Scott Ernst and Dr. Simon Roy Poor

Question Title

* 1. Occupation (please check one):

Question Title

* 2. Please provide the authors names and titles of any CLINICAL TRIALS presented today, CMC 2026 Day 2, that you found impactful and would like more detailed information.

Question Title

* 3. Please rate the sessions as follows in regards to their relevance to you or how it will change your practice.

1. Occupation (please check one):

2. Please provide the authors names and titles of any CLINICAL TRIALS presented today, CMC 2026 Day 2, that you found impactful and would like more detailed information.

3. Please rate the sessions as follows in regards to their relevance to you or how it will change your practice.